Department of Clinical Immunology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil.
Children's Department of Infectious Disease, Oswaldo Cruz University Hospital (HUOC), Universidade de Pernambuco (UPE), Recife, PA, Brazil.
J Clin Immunol. 2022 Nov;42(8):1708-1720. doi: 10.1007/s10875-022-01302-9. Epub 2022 Jul 30.
The Bacille Calmette-Guérin (BCG) vaccine is routinely applied in Brazil. Adverse events (AE) may occur in patients with inborn or acquired immunodeficiencies, varying between local (BCGitis) or disseminated (BCGosis) reactions. We evaluated 53 individuals with local or disseminated adverse events to BCG vaccination to assess if they had inborn errors of immunity (IEI).
Patients diagnosed with an adverse event following BCG vaccination between 2014 and 2017 were included in the study. We collected clinical data, immunophenotyped T and B lymphocytes, and natural killer cells (NK), assessed oxidative function of neutrophils through dihydrorhodamine (DHR) 123 testing, and genotyped 361 genes related to IEI through targeted (panel) sequencing.
The median age of the 53 individuals was four months (IQ 1.5-12), and 52.8% were male. Forty-eight (90.6%) individuals presented only locoregional AE and five (9.4%) presented both locoregional and disseminated AE. Nine (16.9%) patients were diagnosed with an IEI. Four of them presented BCGitis and five presented BCGosis after BCG vaccination. Clinically, four presented chronic granulomatous disease (CGD), three Mendelian susceptibility to mycobacterial disease (MSMD), and two severe combined immunodeficiency (SCID). Patients with IEI had a higher frequency of systemic symptomatology (p = 0.002), history of other infections (p < 0.001), parental consanguinity (p = 0.01), familial history of sick siblings (p < 0.001), or early deaths in the family (p < 0.01).
There is a high frequency of IEI in patients with locoregional and disseminated adverse events to BCG vaccination, revealing the need for the investigation of IEI accompanied by clinical and familial inquiry.
卡介苗(BCG)疫苗在巴西常规接种。在先天或获得性免疫缺陷患者中,可能会出现局部(卡介苗炎)或播散性(卡介苗病)反应的不良反应(AE)。我们评估了 53 例局部或播散性 BCG 疫苗接种后不良反应的患者,以评估他们是否存在先天性免疫缺陷(IEI)。
纳入 2014 年至 2017 年间因 BCG 接种后发生不良反应的患者。我们收集了临床数据,对 T 和 B 淋巴细胞及自然杀伤细胞(NK)进行免疫表型分析,通过二氢罗丹明 123(DHR)检测评估中性粒细胞的氧化功能,并通过靶向(面板)测序对 361 个与 IEI 相关的基因进行基因分型。
53 名患者的中位年龄为 4 个月(IQ 1.5-12),52.8%为男性。48 例(90.6%)患者仅出现局部区域 AE,5 例(9.4%)患者同时出现局部区域和播散性 AE。9 例(16.9%)患者被诊断为 IEI。其中 4 例接种 BCG 后出现卡介苗炎,5 例出现卡介苗病。临床上,4 例表现为慢性肉芽肿病(CGD),3 例表现为孟德尔易感性分枝杆菌病(MSMD),2 例表现为严重联合免疫缺陷(SCID)。IEI 患者更常出现全身症状(p=0.002)、其他感染史(p<0.001)、父母近亲结婚(p=0.01)、家族中患病兄弟姐妹史(p<0.001)或家庭早期死亡史(p<0.01)。
在出现局部和播散性 BCG 疫苗接种后不良反应的患者中,IEI 的发生率较高,这表明需要进行 IEI 调查,并结合临床和家族调查。